Skip to content
MedsAcross

Molecule

Meprobamate

Available on requestControlled substancePsychiatry
Presentations
2
Brands
0
Manufacturers
0
Available from stock
0

Meprobamate is a prescription medicine. It is available as tablets for oral use. MedsAcross supplies Meprobamate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

ATC classification
N05BC01 Meprobamate · Carbamate
US FDA first approval
28 April 1955
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Oral
Dosage forms
Tablet
Identifiers
UNII 9I7LNY769QRxCUI 6760CAS 57-53-4DrugBank DB00371Q418351

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Meprobamate tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.Anxiety or tension associated with the stress of everyday life usually do not require treatment with an anxiolytic. The effectiveness of meprobamate tablets in long-term use, that is,more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

Source: US FDA prescribing information

Dosing overview

Meprobamate Tablets USP: The usual adult daily dosage is 1200 mg to 1600 mg, in three or four divided doses, a daily dosage above 2400mg is not recommended. The usual daily dosage for children ages six to twelve years is 200 mg to 600 mg, in two or three divided doses. Not recommended for children under age 6.

Source: US FDA prescribing information

Contraindications

Acute intermittent porphyria as well as allergic or idiosyncratic reactions to meprobamate or related compounds such as carisoprodol, mebutamate, tybamate, or carbromal.

Source: US FDA prescribing information

Warnings and precautions

Drug Dependence Physical dependence, psychological dependence, and abuse have occurred. When chronic intoxication from prolonged use occurs, it usually involves ingestion of greater than recommended doses and is manifested by ataxia, slurred speech, and vertigo. Therefore, careful supervision of dose and amounts prescribed is advised, as well as avoidance of prolonged administration, especially for alcoholics and other patients with a known propensity for taking excessive quantities of drugs. Sudden withdrawal of the drug after prolonged and excessive use may precipitate recurrence of pre-existing symptoms such as anxiety,anorexia, insomnia, or withdrawal reactions such as vomiting, ataxia,tremors, muscle twitching, confusional states, hallucinosis, and rarely, convulsive seizures.

Source: US FDA prescribing information

Side effects

Central Nervous System Drowsiness, ataxia, dizziness, slurred speech, headache, vertigo,weakness, paresthesias, impairment of visual accommodation,euphoria, overstimulation, paradoxical excitement, fast EEG activity. Gastrointestinal Nausea, vomiting, diarrhea. Cardiovascular Palpitation, tachycardia, various forms of arrhythmia, transient ECG changes, syncope, also hypotensive crisis (including one fatal case). Allergic or Idiosyncratic Allergic or idiosyncratic reactions are usually seen within the period of the first to fourth dose in patients having had no previous contact with the drug. Milder reactions are characterized by an itchy, urticarial, or erythematous maculopapular rash which may be generalized or confined to the groin.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

2 presentations of Meprobamate, sorted by availability.

MedicineManufacturerRegisterAvailability
Meprobamate 200 mg tabletOralGeneric name—US FDAAvailable on request
Meprobamate 400 mg tabletOralGeneric name—US FDAAvailable on request

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 28 April 1955Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Meprobamate in public data. This is not a list of approved uses, see the clinical information.

Questions and answers

Is Meprobamate available for export from India?

Yes, on request. MedsAcross lists 2 presentations of Meprobamate and sources them for licensed hospitals, importers and physicians against valid import documents.

Is Meprobamate approved by the US FDA?

Yes. The US FDA first approved Meprobamate on 28 April 1955, according to Drugs@FDA.

Does Meprobamate need cold chain shipping?

No listed presentation of Meprobamate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Meprobamate in?

Meprobamate is classified under ATC code N05BC01 (Meprobamate).

References

  1. Meprobamate prescribing information (Cipla). U.S. National Library of Medicine, DailyMed. Retrieved 8 July 2026

Request Meprobamate for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.